{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:06:38Z","timestamp":1785182798066,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003827","name":"National Research Development and Innovation Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpba.2026.117441","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:17:33Z","timestamp":1771978653000},"page":"117441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ultra-sensitive HPLC\u2013ESI\u2013MS\/MS quantitation of N-nitroso-phenylephrine in phenylephrine-containing anticold products"],"prefix":"10.1016","volume":"274","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2260-4641","authenticated-orcid":false,"given":"P\u00e1l T.","family":"Szab\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2202-4997","authenticated-orcid":false,"given":"Andr\u00e1s","family":"Darcsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Turczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-7809","authenticated-orcid":false,"given":"Gy\u00f6rgy M.","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117441_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.9734\/jpri\/2025\/v37i117766","article-title":"The efficacy of oral phenylephrine as a decongestant: a systematic review","volume":"37","author":"Nagel","year":"2025","journal-title":"J. Pharm. Res. Int."},{"key":"10.1016\/j.jpba.2026.117441_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2125.2006.02833.x","article-title":"Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse","volume":"63","author":"Eccles","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"35","key":"10.1016\/j.jpba.2026.117441_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40261-015-0311-9","article-title":"Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers","volume":"359","author":"Gelotte","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jpba.2026.117441_bib4","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1002\/j.1875-9114.1993.tb02780.x","article-title":"Pharmacokinetics of oral decongestants","volume":"13","author":"Kanfer","year":"1993","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2026.117441_bib5","unstructured":"FDA proposes ending use of oral phenylephrine as OTC monograph nasal decongestant active ingredient after extensive review., U.S. Food Drug Adm. (n.d.). \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-proposes-ending-use-oral-phenylephrine-otc-monograph-nasal-decongestant-active-ingredient-after\u3009 (accessed December 1, 2025)."},{"key":"10.1016\/j.jpba.2026.117441_bib6","unstructured":"FDA, FDA clarifies results of recent advisory committee meeting on oral phenylephrine, \u3008Https:\/\/Www.Fda.Gov\/Drugs\/Drug-Safety-and-Availability\/Fda-Clarifies-Results-Recent-Advisory-Committee-Meeting-Oral-Phenylephrine\u3009. (2025). \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-clarifies-results-recent-advisory-committee-meeting-oral-phenylephrine\u3009 (accessed December 1, 2025)."},{"key":"10.1016\/j.jpba.2026.117441_bib7","unstructured":"EMA, Nitrosamine impurities | European Medicines Agency, (2019). \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/referral-procedures-human-medicines\/nitrosamine-impurities\u3009 (accessed December 1, 2025)."},{"key":"10.1016\/j.jpba.2026.117441_bib8","unstructured":"Food and Drug Administration, Control of Nitrosamine Impurities in Human Drugs, Guid. Ind. (Revision 1). (2021) 24. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/control-nitrosamine-impurities-human-drugs\u3009 (accessed December 1, 2025)."},{"key":"10.1016\/j.jpba.2026.117441_bib9","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.5153985","article-title":"A review of FDA requirement on recommended acceptable intake limits for nitrosamine drug substance related impurities","author":"Oza","year":"2025","journal-title":"SSRN Electron. J."},{"key":"10.1016\/j.jpba.2026.117441_bib10","first-page":"667","article-title":"ICH M7: assessment and control of DNA reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk","author":"Teasdale","year":"2017","journal-title":"Ich Qual. Guidel. Implement. Guid."},{"key":"10.1016\/j.jpba.2026.117441_bib11","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1021\/acs.chemrestox.4c00234","article-title":"Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices","volume":"37","author":"Manchuri","year":"2024","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2026.117441_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/10408347.2025.2587784","article-title":"Review on LC-MS\/MS methodologies for analysis of N-nitrosamine drug-substance-related impurities","author":"Rajana","year":"2025","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117441_bib13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.38212\/2224-6614.1063","article-title":"A multi-analyte lc-ms\/ms method for screening and quantification of nitrosamines in sartans","volume":"28","author":"Chang","year":"2020","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.jpba.2026.117441_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465176","article-title":"A multianalyte LC-MS\/MS method for accurate quantification of nitrosamines in olmesartan tablets","volume":"1732","author":"Pawar","year":"2024","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2026.117441_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2022.107402","article-title":"Development of an analytical method for the determination and quantification of n-nitrosodimethylamine in olmesartan by HPLC-MS\/MS","volume":"179","author":"Gonz\u00e1lez","year":"2022","journal-title":"Microchem. J."},{"key":"10.1016\/j.jpba.2026.117441_bib16","article-title":"Quantitative analysis of nitrosamine impurities using liquid chromatography tandem mass spectrometry","author":"Satti","year":"2025","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.jpba.2026.117441_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115685","article-title":"A comprehensive LC-UHPLC-MS\/MS method for the monitoring of N-nitrosamines in lipophilic drugs: a case study with rifampicin","volume":"236","author":"de Souza","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117441_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117441_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mas.20298","article-title":"An overview of matrix effects in liquid chromatography-mass spectrometry","volume":"30","author":"Trufelli","year":"2011","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpba.2026.117441_bib20","article-title":"Mitigating matrix effects for LC-MS\/MS quantification of nitrosamine impurities in rifampin and rifapentine","volume":"3","author":"Li","year":"2024","journal-title":"J. Pharm. Biomed. Anal. Open."},{"key":"10.1016\/j.jpba.2026.117441_bib21","unstructured":"ICH Q2(R2) Validation of analytical procedures - Scientific guideline | European Medicines Agency (EMA), (n.d.). \u3008https:\/\/www.ema.europa.eu\/en\/ich-q2r2-validation-analytical-procedures-scientific-guideline\u3009 (accessed February 10, 2026)."},{"key":"10.1016\/j.jpba.2026.117441_bib22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1021\/jasms.2c00022","article-title":"Postcolumn infusion as a quality control tool for LC-MS-based analysis","volume":"33","author":"Gonz\u00e1lez","year":"2022","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jpba.2026.117441_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchromb.2015.06.019","article-title":"Evaluation of the matrix effect of different sample matrices for 33 pharmaceuticals by post-column infusion","volume":"1000","author":"Rossmann","year":"2015","journal-title":"J. Chromatogr. B."},{"issue":"19","key":"10.1016\/j.jpba.2026.117441_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13065-025-01503-4","article-title":"Green and sustainable LC-APCI-MS\/MS method for simultaneous quantification of genotoxic nitrosamines in antidiabetic medication: sitagliptin","volume":"191","author":"Pepakayala","year":"2025","journal-title":"BMC Chem."},{"key":"10.1016\/j.jpba.2026.117441_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chroma.2007.12.045","article-title":"Monitoring of N-nitrosodiethanolamine in cosmetic products by ion-pair complex liquid chromatography and identification with negative ion electrospray ionization mass spectrometry","volume":"1185","author":"Ghassempour","year":"2008","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2026.117441_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27154749","article-title":"NMR assignments of six asymmetrical N-nitrosamine isomers determined in an active pharmaceutical ingredient by DFT calculations","volume":"27","author":"Guan","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2026.117441_bib27","doi-asserted-by":"crossref","first-page":"8799","DOI":"10.1016\/S0040-4020(00)00837-1","article-title":"X-ray crystallographic and proton nuclear magnetic resonance studies of \u03b2-hydroxy-N-nitrosamines derived from \u03b1-amino acids and ephedrine","volume":"56","author":"Hitchcock","year":"2000","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jpba.2026.117441_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/chromsci\/bmab013","article-title":"Stereospecific response of E\/Z-isomers of N-nitrososarcosine in LC-ESI-MS\/MS","volume":"59","author":"Werneth","year":"2021","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2026.117441_bib29","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1021\/ac4016984","article-title":"Analytical methodologies for the detection of sucralose in water","volume":"85","author":"Ferrer","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117441_bib30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.chroma.2008.12.048","article-title":"Sucralose screening in European surface waters using a solid-phase extraction-liquid chromatography\u2013triple quadrupole mass spectrometry method","volume":"1216","author":"Loos","year":"2009","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2026.117441_bib31","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1016\/j.chroma.2010.02.020","article-title":"Analysis of sucralose and other sweeteners in water and beverage samples by liquid chromatography\/time-of-flight mass spectrometry","volume":"1217","author":"Ferrer","year":"2010","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2026.117441_bib32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jfda.2014.01.024","article-title":"Detection of 10 sweeteners in various foods by liquid chromatography\/tandem mass spectrometry","volume":"22","author":"Chang","year":"2014","journal-title":"J. Food Drug Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:08:45Z","timestamp":1777572525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["S0731708526001093"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117441","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultra-sensitive HPLC\u2013ESI\u2013MS\/MS quantitation of N-nitroso-phenylephrine in phenylephrine-containing anticold products","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117441"}}